Efficacy and safety of Atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (April-SLE randomised trial)
- Author(s): Wofsy, David
- Isenberg, D
- Gordon, C
- Licu, D
- Copt, S
- Rossi, CP
- et al.
Published Web Locationhttp://europepmc.org/articles/PMC4680140?pdf=render
Objectives: Despite advances in systemic lupus erythematosus (SLE) treatment, many patients suffer from the disease and side effects. Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferationinducing ligand, which are increased
Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.